Table 1.
Pivotal therapeutic trials for infiltrating gliomas
| AUTHOR | YEAR | PHASE | HISTOLOGY | TREATMENTS | OS | PFS |
|---|---|---|---|---|---|---|
| Newlands1 | 1992 | I | Recurrent glioma, melanoma, renal cancer, breast cancer, colorectal cancer, stomach cancer, other cancers | TMZ | NA | NA |
| Bower2 | 1997 | II | Recurrent AA/GBM | TMZ | 5.8 months | 4.2 months |
| Yung3 | 2000 | II | Recurrent GBM | TMZ procarbazine |
NA | 12.4 weeks 8.32 weeks |
| Stupp5 | 2002 | II | Newly Dx GBM | RT/TMZ+TMZ | 16 months | NA |
| Stupp6 | 2005 | III | Newly Dx GBM | RT/TMZ+TMZ RT alone |
14.6 months 12.1 months |
6.9 months 5.0 months |
| Gilbert11 | 2014 | III | Newly Dx GBM | RT/TMZ+TMZ (5/28 day) RT/TMZ+TMZ (21/28 day) |
16.6 months 14.9 months |
5.5 months 6.7 months |
| Wick15 | 2012 | III | Grade III/IV Newly Dx GBM | RT (60 Gy) TMZ (7day on, 7 day off) |
9.6 months 8.6 months |
NA NA |
| Malmstrom16 | 2012 | III | Newly Dx GBM | RT (60 Gy) RT (34 Gy) TMZ (5/28 days) |
6 months 7.5 months 8.3 months |
NA NA NA |
| Brandes17 | 2003 | NA | Newly Dx GBM | RT (59.4 Gy) RT (59.4Gy)+PCV RT (59.4 Gy)+TMZ (5/28 day) |
11.2 months 12.7 months 14.9 months |
NA NA NA |
| Minniti18 | 2008 | II | Newly Dx GBM | RT (60 Gy)/TMZ+TMZ (5/28 day) | 10.6 months | 7 months |
| Minniti19 | 2009 | II | Newly Dx GBM | RT (30 Gy)+TMZ (5/28 day) | 9.3 months | 6.3 months |
| Perry*20 | 2016 | III | Newly Dx GBM | RT (40 Gy)/TMZ+TMZ (5/28 day) RT (40 Gy) |
9.3 months 7.6 months |
5.3 months 3.9 months |
| Friedman22 | 2009 | II | Recurrent GBM | bev bev+irinotecan |
9.7 months 8.9 months |
4.2 months 5.6 months |
| Kreisl25 | 2009 | II | Recurrent GBM | bev followed by bev+irinotecan | 31 weeks | 16 weeks |
| Taal26 | 2014 | II | Recurrent GBM | bev CCNU bev+CCNU |
8 months 8 months 12 months |
3 months 1 month 4 months |
| Wick*27 | 2015 | III | Recurrent GBM | CCNU bev+CCNU |
8.6 months 9.1 months |
1.5 months 4.2 months |
| Gilbert29 | 2014 | III | Newly Dx GBM | RT/TMZ/bev+TMZ/bev RT/TMZ+TMZ |
15.7 months 16.1 months |
10.7 months 7.3 months |
| Chinot30 | 2014 | III | Newly Dx GBM | RT/TMZ/bev+TMZ/bev RT/TMZ+TMZ |
16.8 months 16.7 months |
10.6 months 6.2 months |
| Brem37 | 1991 | I/II | Recurrent grade III/IV glioma | BCNU wafers | 46 weeks | NA |
| Brem38 | 1995 | III | Recurrent grade III/IV glioma | BCNU wafers Surgery+placebo |
31 weeks 23 weeks |
NA NA |
| Westphal40 | 2003 | III | GBM, AA, AO, AOA | BCNU wafers Surgery+placebo |
11.9 months 13.6 months |
5.9 months 5.9 months |
| Stupp44 | 2012 | III | Recurrent GBM | TTF Physician’s choice chemotherapy |
6.6 months 6.0 months |
2.2 months 2.1 months |
| Stupp45 | 2015 | III | Newly Dx GBM | RT/TMZ+TMZ/TTF RT/TMZ+TMZ |
19.6 months 16.6 months |
7.1 months 4.0 months |
| Van Den Bent48 | 2013 | III | AO | RT+PCV RT alone |
43.2 months 30.6 months |
24.3 months 13.2 months |
| Cairncross46,49 | 2013 | III | AO, AOA | PCV+RT RT alone |
4.7 years 4.6 years |
2.6 years 1.7 years |
| Buckner52 | 2016 | III | O, OA, A | RT+PCV RT alone |
13.3 years 7.8 years |
10.4 years 4.0 years |
| Fisher54 | 2015 | II | O, OA, A | RT/TMZ+TMZ | NA | 4.5 years |
Overall survival, OS; progression free survival, PFS; not available, NA; glioblastoma, GBM; anaplastic astrocytoma, AA; anaplastic oligodendroglioma, AO; anaplastic oligoastrocytoma, AOA; astrocytoma, A, oligodendroglioma, O; oligoastrocytoma, OA; temozolomide, TMZ; bevacizumab, bev; tumor treating fields, TTF; procarbazine/CCNU/ vincristine, PCV; diagnosed, Dx.
*currently only in abstract form.